Viatris VTRS
United StatesHealthcare · Drug Manufacturers - Specialty & GenericUSD
19.70 USD (+12.6%)
10 analysts
Trading 2120.30 €Open account ↗
Lightyear0.90 €Open account ↗
N260.90 €Open account ↗
XTB1.00 €★ featured · affiliateOpen account ↗Trading 2120.30 €Open account ↗Lightyear0.90 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
Viatris Inc. is a global pharmaceutical company that develops, manufactures, and markets branded, generic, and biosimilar medicines, with a business model focused on access to affordable therapies across multiple therapeutic areas.
Key points
from its scores- ✓Good share-price trend9.6
- ✕Little or no dividend3.0
- ✕Little competitive advantage4.4
- !Somewhat demanding valuation5.0
AI analysis
bottom line, main risk, context and newsThe cheap valuation and positive momentum partially offset balance sheet and governance risks, but dividend sustainability and return on capital are key concerns.
Viatris presents an attractive valuation (forward P/E of 6.54, FCF yield of 13.33%) and strong momentum (75.45% over 12 months), but its financial health is fragile due to high leverage (Net Debt/EBITDA of 2.82) and a negative ROE (-2.75%), with an unsustainable dividend (payout of 960%).
The main risk is high leverage (Net Debt/EBITDA of 2.82) combined with a negative ROE and a 960% payout, which could lead to a dividend cut or refinancing issues if rates continue to rise.
Context and risks
Viatris operates in the U.S. pharmaceutical sector, subject to regulatory pressure on drug pricing and an active legal environment. Its high leverage (Net Debt/EBITDA of 2.82) and exposure to opioid litigation in the U.S. add specific governance and legal risk not captured by financial metrics.
Is Viatris stock cheap or expensive?
at the analysis dateOn EV / EBITDA, it trades 48% below the Healthcare median.
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| EV / EBITDA | 7.5 | 14.5 | −48% |
| Price / book | 1.4 | 4.1 | −66% |
| Price / sales | 1.4 | 3.4 | −60% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 5.0 out of 10 (median for Healthcare: 4.7).
Average analyst target: 19.70 USD, +12.6% versus the price.
A discount may reflect more risk or slower growth than its sector: Financial health 5.8 (sector 6.5), Growth 5.6 (sector 6.6).
Classic formulas with standard assumptions (5.0% growth, 8-9% discount rate). Indicative only: they change a lot with the assumptions and are not a recommendation.
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- Forward P/E
- 6.5
- EV / EBITDA
- 7.5
- Price / book
- 1.4
- Price / sales
- 1.4
- PEG
- 3.19
- Market cap
- 20.1B USD
- Enterprise value
- 32.3B USD
Profitability
- ROE
- −2.8%
- ROA
- 2.7%
- ROIC (approx.)
- 6.6%
- Gross margin
- 40.3%
- Operating margin
- 12.6%
- Net margin
- −2.8%
- Free cash flow
- 2.7B USD
- FCF yield
- 13.3%
- Cash conversion
- 62%
Solvency
- Total debt
- 13.6B USD
- Net debt
- 12.1B USD
- Cash
- 1.5B USD
- EBITDA
- 4.3B USD
- Net debt / EBITDA
- 2.82
- Debt / equity
- 95.53
- Current ratio
- 1.58
- Quick ratio
- 0.82
Growth
- Revenue growth
- +4.9%
- EPS (TTM)
- −0.36 USD
- EPS (forward)
- 2.67 USD
Dividend
- Dividend yield
- 2.7%
- Payout
- 960.0%
Risk and market
- Beta
- 0.86
- Analyst consensus
- Buy (10)
- Target price
- 19.70 USD
- 52-week range
- 9.69 – 18.43
Recent news
All VTRS news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about Viatris
Is Viatris stock cheap or expensive?
On EV / EBITDA, it trades 48% below the Healthcare median. Valuation score: 5.0 out of 10 (median for Healthcare: 4.7). Average analyst target: 19.70 USD, +12.6% versus the price. This is not investment advice.
What score does Viatris get on MeridIAn Screener?
It scores 5.4 out of 10, rank 1,513 of 2,130 (better than 29% of the companies analysed). Its strongest category is Momentum (9.6) and its weakest, Dividend (3.0). Analysis of 08/10/2026.
How much is Viatris worth on the stock market?
Its market capitalisation is 20.1B USD and its enterprise value, debt included, is 32.3B USD.
How much debt does Viatris have?
Its net debt (debt minus cash) is 12.1B USD. That is 2.82 times its EBITDA; the Healthcare median is 1.53.
Does Viatris pay a dividend?
Yes: its dividend yield is 2.74% and it pays out 960% of its earnings.
How has Viatris stock performed over the last year?
It has risen 85.9% over the last year, excluding dividends. Over the last 52 weeks it has traded between 9.69 and 18.43 USD. Past performance does not guarantee future results.
What do analysts think of Viatris?
10 analysts cover it; their average recommendation is “Buy” and their average target is 19.70 USD (+12.6% versus the price). It is an estimate, not market data.